Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Indacaterol→

Indacaterol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
312753-06-3
Molecular formula
C24H28N2O3
Molecular weight
392.5 g/mol
Drug class
Ultra-long-acting beta-2 adrenergic receptor agonist (LABA)bronchodilator
Mechanism of action
Stimulates beta-2 adrenergic receptors in bronchial smooth muscle, increasing intracellular cyclic AMP and producing prolonged bronchodilation.
Indications / reported uses
  • Long-term maintenance bronchodilator treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD); not indicated for relief of acute bronchospasm or as asthma monotherapy

Sources: EMA EPAR — Onbrez Breezhaler (indacaterol) · US DailyMed — Indacaterol products · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Indacaterol Environmental Risk Assessment (ERA) (the Indacaterol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.